EATG » ViiV Healthcare announces week 48 results from TANGO study

ViiV Healthcare announces week 48 results from TANGO study

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019)

Read the full press release here.


 

Source:
ViiV Healthcare
News categories: HIV treatment